Integration of a novel anti-PD-1 antibody with chimeric antigen receptor-T engineered to express interleukin-7 enhances targeting efficacy against lung cancer
Life Medicine · 05.12.2025 · 4 (6)
DOI: 10.1093/lifemedi/lnaf035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Medicine, online erschienen am 23.12.2025. Verfasst von Chenxi Cheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Organ Regeneration and Reconstruction, State Key Laboratory of Stem Cell and Reproductive Biology, Institute for Stem Cell and Rege…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T cell therapy has emerged as a promising approach for hematological malignancies, yet its efficacy in solid tumors is hindered by limited persistence. To address this, immune checkpoint inhibitors (ICIs) and cytokines have been explored as potential solutions. In this study, we developed a novel monoclonal antibody (mAb), m8A8, which exhibits high specificity for human PD-1 and effectively disrupts its ligand interactions. Furthermore, we engineered CAR-T cells to express human IL-7, resulting in enhanced anti-tumor efficacy in xenograft models. Additionally, the human–mouse chimeric antibody C8A8, derived from m8A8, was found to significantly amplify the anti-tumor activity of IL-7-engineered CAR-T cells. Our findings provide compelling evidence and a robust rationale for the synergistic integration of ICIs, cytokines, and CAR-T cell therapy in the treatment of solid tumors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Organ Regeneration and Reconstruction, State Key Laboratory of Stem Cell and Reproductive Biology, Institute for Stem Cell and Regeneration, Institute of Zoology, Chinese Academy of Sciences, Beijing 1…
- University of Chinese Academy of Sciences, Beijing 100049, China.
- Beijing Institute for Stem Cell and Regenerative Medicine, Beijing 100101, China.
ORCID-Profile: Tongbiao Zhao
Zitieren
APA
Cheng, C., Zhang, L., Cao, J., Li, X., Wen, Y., Liu, K., & Zhao, T. (2025). Integration of a novel anti-PD-1 antibody with chimeric antigen receptor-T engineered to express interleukin-7 enhances targeting efficacy against lung cancer. Life Medicine, 4(6). https://doi.org/10.1093/lifemedi/lnaf035
Vancouver
Cheng C, Zhang L, Cao J, Li X, Wen Y, Liu K, et al. Integration of a novel anti-PD-1 antibody with chimeric antigen receptor-T engineered to express interleukin-7 enhances targeting efficacy against lung cancer. Life Medicine. 2025;4(6). doi:10.1093/lifemedi/lnaf035
BibTeX
@article{Cheng2025,
author = {Cheng, Chenxi and Zhang, Lin and Cao, Jiani and Li, Xiaoyan and Wen, Ya and Liu, Kun and Zhao, Tongbiao},
title = {Integration of a novel anti-PD-1 antibody with chimeric antigen receptor-T engineered to express interleukin-7 enhances targeting efficacy against lung cancer},
journal = {Life Medicine},
year = {2025},
volume = {4},
number = {6},
doi = {10.1093/lifemedi/lnaf035}
}
EUVIMED